pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CRISPR/Cas9 · news · pharmadog
← back to CRISPR/Cas9
News · CRISPR/Cas9
180
stories
Sep 23, 26
ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s hands
biospace
Sep 15, 26
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
fiercebiotech
Sep 15, 26
Blood centers can help biopharma scale cell and gene therapies
biospace
Sep 14, 26
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
biopharma dive
Sep 14, 26
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
fiercebiotech
Sep 14, 26
After a brief storm of political headwinds, mRNA is back with strong momentum
biospace
Sep 10, 26
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
Sep 10, 26
A booming business on Wall Street would love more biotechs to quietly die
biopharma dive
Sep 8, 26
Moonwalk reloads with $70M and new RNAi prospects for obesity
biopharma dive
Sep 8, 26
Moonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinic
biospace
Sep 8, 26
Diabetes cell therapy biotechs Sernova and Seraxis to merge
endpoints
Sep 4, 26
10 life sciences startups selected for accelerator program
biospace
Sep 3, 26
US to grant up to $125M for personalized RNA manufacturing innovation
biospace
Sep 2, 26
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
biopharma dive
Sep 2, 26
China deaths reignite debate about using viruses to deliver CRISPR therapies
endpoints
Sep 2, 26
Typewriter raises $56M for jumping gene technology and in vivo CAR-T therapies
endpoints
Sep 1, 26
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
biospace
Aug 28, 26
#ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy
endpoints
Aug 27, 26
CAR Ts will only treat autoimmune diseases if we can scale delivery
biospace
Aug 26, 26
An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapies
endpoints
Aug 25, 26
Biotech IPOs approach ‘escape velocity’ barring yellow flags that could threaten rebound
biospace
Aug 24, 26
News on AstraZeneca, Cytokinetics, Novartis — what to look out for at ESC 2026
endpoints
Aug 21, 26
Lawmakers urge FDA to enact new China policies after 3 gene therapy trial deaths
biospace
Aug 20, 26
Scribe’s early-stage IPO standout defies biotech’s derisking trend
biospace
Aug 20, 26
Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
stat
Aug 19, 26
STAT+: Experts scrutinize Huidagene’s disclosures after patient death
stat
Aug 19, 26
STAT+: Regeneron drug for disease that causes dangerous bone growth earns FDA approval
stat
Aug 19, 26
STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
stat
Aug 19, 26
STAT+: In wake of boy’s death, gene editing experts dissect Huidagene’s decisions
stat
Aug 14, 26
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
← prev
page 3 of 6
next →